|
End-of-day quote
Shanghai S.E.
30/10/2026
|
5-day change | 1st Jan Change | ||
| 20.26 CNY | +9.99% |
|
+11.56% | +14.98% |
| 10-29 | Sipai Health Technology Unit to Sell Pharmacy Operator to DaShenLin Pharmaceutical | MT |
| 10-23 | DaShenLin Pharmaceutical Completes Maturity Redemption of Convertible Bonds | MT |
Company Valuation: DaShenLin Pharmaceutical Group Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 33,307 | 37,585 | 28,359 | 17,151 | 20,066 | 23,073 | - | - |
| Change | - | 12.85% | -24.55% | -39.52% | 17% | 14.98% | - | - |
| Enterprise Value (EV) 1 | 32,838 | 36,233 | 27,369 | 15,778 | 16,831 | 19,733 | 19,313 | 19,018 |
| Change | - | 10.34% | -24.46% | -42.35% | 6.67% | 17.24% | -2.13% | -1.53% |
| P/E | 42.1x | 36.3x | 24.2x | 18.6x | 16.3x | 15.5x | 13.5x | 11.9x |
| PBR | 6.3x | 6.24x | 4.16x | 2.49x | 2.72x | 2.94x | 2.7x | 2.51x |
| PEG | - | 1.2x | 1.8x | -0.9x | 0.5x | 0.7x | 0.9x | 0.9x |
| Capitalization / Revenue | 1.99x | 1.77x | 1.16x | 0.65x | 0.73x | 0.78x | 0.71x | 0.64x |
| EV / Revenue | 1.96x | 1.71x | 1.12x | 0.6x | 0.61x | 0.67x | 0.59x | 0.53x |
| EV / EBITDA | 13.6x | 19.2x | 12.9x | 4.65x | 4.39x | 5.16x | 4.59x | 4.09x |
| EV / EBIT | 31.6x | 25.5x | 16.8x | 10.5x | 8.26x | 8.49x | 7.31x | 6.34x |
| EV / FCF | 117x | 13.1x | 19.7x | 9.51x | 3.44x | 11.4x | 6.91x | 5.85x |
| FCF Yield | 0.86% | 7.61% | 5.09% | 10.5% | 29.1% | 8.74% | 14.5% | 17.1% |
| Dividend per Share 2 | 0.3472 | 0.5 | 0.31 | 0.31 | 0.49 | 0.9418 | 1.043 | 1.222 |
| Rate of return | 1.19% | 1.52% | 1.24% | 2.06% | 2.78% | 4.65% | 5.15% | 6.03% |
| EPS 2 | 0.6944 | 0.9083 | 1.03 | 0.81 | 1.08 | 1.304 | 1.5 | 1.701 |
| Distribution rate | 50% | 55% | 30.1% | 38.3% | 45.4% | 72.2% | 69.5% | 71.8% |
| Net sales 1 | 16,759 | 21,248 | 24,531 | 26,497 | 27,502 | 29,540 | 32,521 | 35,823 |
| EBITDA 1 | 2,408 | 1,883 | 2,119 | 3,395 | 3,833 | 3,828 | 4,204 | 4,651 |
| EBIT 1 | 1,041 | 1,421 | 1,632 | 1,501 | 2,038 | 2,324 | 2,643 | 2,997 |
| Net income 1 | 791.2 | 1,036 | 1,166 | 914.8 | 1,235 | 1,486 | 1,711 | 1,937 |
| Net Debt 1 | -469.2 | -1,352 | -989.8 | -1,373 | -3,236 | -3,340 | -3,760 | -4,056 |
| Reference price 2 | 29.24 | 33.00 | 24.90 | 15.06 | 17.62 | 20.26 | 20.26 | 20.26 |
| Nbr of stocks (in thousands) | 1,138,968 | 1,138,947 | 1,138,902 | 1,138,848 | 1,138,848 | 1,138,855 | - | - |
| Announcement Date | 4/27/22 A | 4/27/23 A | 4/28/24 A | 4/25/25 A | 4/23/26 A | - | - | - |
1CNY in Million2CNY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 15.54x | 0.67x | 5.16x | 4.65% | 3.47B | |
| 17.23x | 0.71x | 10.57x | -.--% | 15.49B | |
| 16.95x | 0.75x | 7.86x | 2.21% | 6.5B | |
| 21.09x | 0.36x | 5.55x | 2.16% | 6.44B | |
| 19.43x | 0.7x | 12.14x | 1.12% | 5.82B | |
| 17.7x | 0.78x | 8.49x | 2.54% | 4.9B | |
| 17x | 1.07x | 7.49x | 2.48% | 4.82B | |
| 14.43x | 1.23x | 7.57x | 5.63% | 3.16B | |
| 17.15x | 0.36x | 5.61x | 1.34% | 3.08B | |
| 14.9x | 0.43x | 7.14x | 1.41% | 3.04B | |
| Average | 17.14x | 0.71x | 7.76x | 2.35% | 5.67B | |
| Weighted average by Cap. | 17.49x | 0.70x | 8.46x | 1.79% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 603233 Stock
- Valuation DaShenLin Pharmaceutical Group Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
